Produces and sells cannabis products in Canada and internationally under brands like Spinach and PEACE NATURALS.
Produces and sells cannabis products in Canada and internationally under brands like Spinach and PEACE NATURALS.
Canadian sales go to provincial wholesalers, which supply licensed shops, so the company sets wholesale prices but not shelf prices. Medical cannabis is exported to markets such as Israel and Germany. Altria, the tobacco company, is the largest shareholder; this Toronto line trades the same company as the US-listed shares.
Moat: none (brand). Recognizable recreational brand in a commoditized, oversupplied Canadian cannabis market.
Headquarters: Toronto, Canada · Employees: 610
Size Cronos (CRON.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $1.17B, the 219th largest of 405 Canada companies the cockpit tracks. Shares closed at C$4.57 on 18 Nov 2026.
Performance Over six months the shares gained 23.9%, against -13.9% for the median peer and +1.1% for the Canada market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 54.7% over the last twelve months (peer median +4.6%); the operating margin is 4.9% (peer median 14.4%).
Valuation It trades at 16.2× forward earnings against a peer median of 18.4× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.5 points below its cost of capital (10.2% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$286M | C$205M | C$161M | C$118M | C$113M |
| Revenue growth | — | +27% | +37% | +4% | — |
| Gross profit | C$131M | C$84.7M | C$29.5M | C$9.27M | C$12.3M |
| EBITDA | C$35.4M | -C$4.61M | -C$67.4M | -C$97.2M | -C$119M |
| Net income | C$80.1M | -C$13.2M | C$56.3M | -C$99.7M | -C$219M |
| Free cash flow | C$90.7M | C$208,200 | C$8.81M | -C$59.0M | -C$120M |
| Capital expenditure | C$22.1M | C$36.4M | C$18.0M | C$4.62M | C$6.55M |
| Total debt | C$1.72M | C$2.07M | C$2.90M | C$3.37M | C$5.25M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cronos CRON.TO | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% |
| Canopy Growth WEED.TO | n/a | -50% | n/a | n/a | n/a | n/a |
| Tilray Brands TLRY.TO | $333M | -56% | +17% | -6% | n/a | n/a |
| Aurora Cannabis ACB.TO | n/a | +32% | n/a | n/a | n/a | n/a |
| Village Farms International VFF | n/a | -16% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRON.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | -3.7% | 9th highest of 21 |
| 6-month return | +23.9% | -13.9% | 5th highest of 21 |
| Distance from 52-week high | -16.4% | -34.6% | 6th highest of 21 |
| Revenue growth (TTM) | +54.7% | +4.6% | 2nd highest of 21 |
| Operating margin | 4.9% | 14.4% | 6th lowest of 21 |
| Forward P/E | 16.2× | 18.4× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 18.8% | 2.8% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +26.7% | +11.9% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | -8.0 pp | -10.5 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | -8.5 pp | +2.7 pp | lowest of 21 |
| EV / EBITDA | 19.6× | 17.4× | 4th most expensive of 10 |
| Net debt / EBITDA | -29.8× | -0.7× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |